Improved oxacillin treatment outcomes in experimental skin and lung infection by a methicillin-resistant Staphylococcus aureus isolate with a vraSR operon deletion
about
Phosphorylation-dependent conformational changes and domain rearrangements in Staphylococcus aureus VraR activationMultidrug resistance operon emrAB contributes for chromate and ampicillin co-resistance in a Staphylococcus strain isolated from refinery polluted river bank.Staphylococcus aureus methicillin-resistance factor fmtA is regulated by the global regulator SarA.Combination approaches to combat multidrug-resistant bacteria.Overcoming resistance to β-lactam antibiotics.Small-molecule inhibition of bacterial two-component systems to combat antibiotic resistance and virulence.Activity of oxacillin versus that of vancomycin against oxacillin-susceptible mecA-positive Staphylococcus aureus clinical isolates evaluated by population analyses, time-kill assays, and a murine thigh infection model.VraT/YvqF is required for methicillin resistance and activation of the VraSR regulon in Staphylococcus aureus.Comparative virulence studies and transcriptome analysis of Staphylococcus aureus strains isolated from animals.Targeting cell membrane adaptation as a novel antimicrobial strategy.VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivo-selected clinical strains of methicillin-resistant Staphylococcus aureus.The role of the Staphylococcal VraTSR regulatory system on vancomycin resistance and vanA operon expression in vancomycin-resistant Staphylococcus aureus.Potent small-molecule suppression of oxacillin resistance in methicillin-resistant Staphylococcus aureus.Dual roles of FmtA in Staphylococcus aureus cell wall biosynthesis and autolysis
P2860
Q27678021-6F08D03D-31A5-4416-A21D-A74C4D0AEA21Q33458654-E1B3BE11-86E6-4031-BF7E-C080880A19F9Q34406036-174F5932-2A4B-40A3-8268-A8C30915829EQ34554879-6A2CE4B1-F718-43E8-B1F9-9999B2A44025Q34636678-F540476C-7FE4-464B-9026-0E557A759236Q34823364-65DD449F-3A0F-4C3A-A08E-2FA41E33EFB5Q36018823-08FB8C72-E5DB-4AEE-82FE-88A5FF8B1510Q36505489-BF27F4A0-25EF-4735-8D30-0E418AF5D720Q37339803-028DC627-6F02-4D5D-812E-5FD00269FDD3Q38908726-331AC1C1-2A45-47C7-BCF6-957D41039168Q40327375-370F1595-E810-4700-9107-2FC1EEA84CCAQ41874395-5C026D42-B503-4CEA-AB62-086E3F93ACCAQ41895801-4E5CEDEB-60C2-4D17-9751-2EF9D1CD80C9Q42132010-AE0481DF-A681-47C3-A68F-D5C8BDF193DE
P2860
Improved oxacillin treatment outcomes in experimental skin and lung infection by a methicillin-resistant Staphylococcus aureus isolate with a vraSR operon deletion
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Improved oxacillin treatment o ...... e with a vraSR operon deletion
@ast
Improved oxacillin treatment o ...... e with a vraSR operon deletion
@en
type
label
Improved oxacillin treatment o ...... e with a vraSR operon deletion
@ast
Improved oxacillin treatment o ...... e with a vraSR operon deletion
@en
prefLabel
Improved oxacillin treatment o ...... e with a vraSR operon deletion
@ast
Improved oxacillin treatment o ...... e with a vraSR operon deletion
@en
P2093
P2860
P356
P1476
Improved oxacillin treatment o ...... e with a vraSR operon deletion
@en
P2093
Christopher P Montgomery
Robert S Daum
Shaohui Yin
Susan Boyle-Vavra
P2860
P304
P356
10.1128/AAC.01704-10
P407
P50
P577
2011-03-07T00:00:00Z